JP5431151B2 - 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬 - Google Patents

血管障害および加齢黄斑変性症の治療および診断のための方法および試薬 Download PDF

Info

Publication number
JP5431151B2
JP5431151B2 JP2009519713A JP2009519713A JP5431151B2 JP 5431151 B2 JP5431151 B2 JP 5431151B2 JP 2009519713 A JP2009519713 A JP 2009519713A JP 2009519713 A JP2009519713 A JP 2009519713A JP 5431151 B2 JP5431151 B2 JP 5431151B2
Authority
JP
Japan
Prior art keywords
gene
cfhr1
cfhr3
deletion
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009519713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544280A5 (enExample
JP2009544280A (ja
Inventor
グレゴリー エス． ヘイジマン
Original Assignee
ユニバーシティー オブ アイオワ リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5431151(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ユニバーシティー オブ アイオワ リサーチ ファンデーション filed Critical ユニバーシティー オブ アイオワ リサーチ ファンデーション
Publication of JP2009544280A publication Critical patent/JP2009544280A/ja
Publication of JP2009544280A5 publication Critical patent/JP2009544280A5/ja
Application granted granted Critical
Publication of JP5431151B2 publication Critical patent/JP5431151B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/329—Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
JP2009519713A 2006-07-13 2007-07-13 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬 Active JP5431151B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83101806P 2006-07-13 2006-07-13
US60/831,018 2006-07-13
US84007306P 2006-08-23 2006-08-23
US60/840,073 2006-08-23
PCT/US2007/073514 WO2008008986A2 (en) 2006-07-13 2007-07-13 Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration

Publications (3)

Publication Number Publication Date
JP2009544280A JP2009544280A (ja) 2009-12-17
JP2009544280A5 JP2009544280A5 (enExample) 2010-09-02
JP5431151B2 true JP5431151B2 (ja) 2014-03-05

Family

ID=38924245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009519713A Active JP5431151B2 (ja) 2006-07-13 2007-07-13 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬

Country Status (11)

Country Link
US (4) US7867727B2 (enExample)
EP (3) EP2447275B1 (enExample)
JP (1) JP5431151B2 (enExample)
AT (1) ATE551350T1 (enExample)
AU (1) AU2007272335B2 (enExample)
CA (1) CA2659392A1 (enExample)
DK (1) DK2447275T3 (enExample)
IL (1) IL196319A0 (enExample)
NZ (1) NZ574046A (enExample)
SG (1) SG173371A1 (enExample)
WO (1) WO2008008986A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2357257B1 (en) 2005-02-14 2019-07-31 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
US20080146501A1 (en) * 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
MX2009000909A (es) * 2006-07-26 2009-02-04 Univ Yale Diagnostico y tratamiento de degeneracion macular relacionada con la edad.
CA2704809A1 (en) * 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
US20090186370A1 (en) * 2008-01-18 2009-07-23 Ogle Matthew F Diagnostic biomarkers for vascular aneurysm
DE102008049136B4 (de) * 2008-09-26 2012-10-25 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Neue Regulatoren des angeborenen Immunsystems
JP2012533562A (ja) * 2009-07-16 2012-12-27 グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド 治療法
WO2011017229A2 (en) * 2009-08-06 2011-02-10 Tufts - New England Medical Center Plasma complement components as expression markers for age-related macular degeneration and related phenotypes
WO2011029954A2 (de) * 2009-09-14 2011-03-17 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen
JP5706612B2 (ja) * 2009-12-28 2015-04-22 学校法人 埼玉医科大学 加齢黄斑変性症易罹患性の判定マーカー並びに判定方法及び判定キット
WO2012051462A2 (en) * 2010-10-14 2012-04-19 Sequenom, Inc. Complement factor h copy number variants found in the rca locus
WO2012112955A2 (en) * 2011-02-17 2012-08-23 The Trustees Of Columbia University In The City Of New York Methods for identifying subjects with a genetic risk for developing iga nephropathy
CN103874526A (zh) * 2011-04-29 2014-06-18 犹他大学研究基金会 预测补体介导的疾病的发展的方法
JP2013064616A (ja) * 2011-09-15 2013-04-11 Osaka Univ 高度動脈硬化を発症している可能性を検出する方法およびその利用
WO2013150132A2 (de) * 2012-04-05 2013-10-10 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnostik und beurteilung von schlaganfällen
GB201301632D0 (en) * 2013-01-30 2013-03-13 Imp Innovations Complement System
EP2962106A1 (en) * 2013-02-26 2016-01-06 Roche Diagnostics GmbH Agents, kits and methods for complement factor h-related protein 1 detection
US10202647B2 (en) 2013-04-12 2019-02-12 The Trustees Of Columbia University In The City Of New York Mutations in DSTYK cause dominant urinary tract malformations
WO2014194213A1 (en) * 2013-05-30 2014-12-04 University Of Iowa Research Foundation Specific complement proteins and efficacy of antibody therapy
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
JP7199966B2 (ja) 2015-12-23 2023-01-06 ソルボンヌ ウニベルシテ ＣＤ１１ｂ／ＣＤ１８に対するＣＦＨの結合を阻害する薬剤、およびその使用
US11142548B2 (en) 2016-05-10 2021-10-12 Sorbonne Universite Agents that activate CD47 and their use in the treatment of inflammation
WO2019215330A1 (en) * 2018-05-10 2019-11-14 The University Of Manchester Methods for assessing macular degeneration
EP3824095A4 (en) 2018-07-20 2022-04-20 University of Utah Research Foundation GENE THERAPY FOR MACULATE GENERATION
DE102018120016B4 (de) 2018-08-16 2020-09-03 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung
US20220146530A1 (en) * 2019-03-07 2022-05-12 Reti Mark Co., Ltd. A combination of biomarkers for diagnosing of age-related macular degeneration and use thereof
CN113966401A (zh) 2019-04-10 2022-01-21 犹他大学研究基金会 用于治疗amd的htra1调节
KR20230019062A (ko) * 2019-10-22 2023-02-07 어플라이드 제네틱스 테크놀로지스 코퍼레이션 연령-관련 황반 변성 및 다른 안구 질환 및 장애의 치료를 위한 아데노-연관 바이러스 (aav) 벡터
EP4214515A1 (en) * 2020-09-16 2023-07-26 Complement Therapeutics Limited Complementome assay

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5037746A (en) 1986-12-03 1991-08-06 University Patents, Inc. RNA ribozyme polymerases, and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
EP0451141B1 (en) 1988-05-20 1998-11-18 F. Hoffmann-La Roche Ag Immobilized sequence-specific probes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US20020032313A1 (en) * 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
EP0512733A2 (en) 1991-05-03 1992-11-11 Washington University Modified complement system regulator
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0655090B1 (en) 1992-04-27 2000-12-27 The Trustees Of Dartmouth College Detection of gene sequences in biological fluids
JPH08505872A (ja) 1993-01-22 1996-06-25 ユニバーシティ・リサーチ・コーポレイション 治療剤の局所化
US5667969A (en) 1993-11-12 1997-09-16 University Research Corporation Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6706471B1 (en) 1996-01-24 2004-03-16 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1068311B2 (en) 1998-04-08 2020-12-09 Commonwealth Scientific and Industrial Research Organisation Methods and means for obtaining modified phenotypes
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
WO2001006262A1 (en) 1999-02-19 2001-01-25 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
EP1309726B2 (en) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
EP2026073B1 (en) 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US6632606B1 (en) 2000-06-12 2003-10-14 Aclara Biosciences, Inc. Methods for single nucleotide polymorphism detection
RU2322500C2 (ru) 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
AU2002326581A1 (en) 2001-08-10 2003-03-03 University Of Virginia Patent Foundation Enhancing the efficacy of immunotherapies by supplementing with complement
WO2006062716A2 (en) * 2004-11-18 2006-06-15 Yale University Methods and compositions for treating ocular disorders
EP2357257B1 (en) 2005-02-14 2019-07-31 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
AU2006254979B2 (en) 2005-06-08 2011-11-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26
EP1943363A1 (en) 2005-10-11 2008-07-16 Yale University Genes associated with macular degeneration
AU2006311966A1 (en) 2005-11-02 2007-05-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method evolved for recognition and testing of age related macular degeneration (MERT-ARMD)
US20080146501A1 (en) 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
GB0611606D0 (en) * 2006-06-13 2006-07-19 Univ Belfast Protection against and treatment of age related macular degeneration

Also Published As

Publication number Publication date
EP2479284B1 (en) 2017-09-20
DK2447275T3 (en) 2015-06-29
IL196319A0 (en) 2009-09-22
EP2479284A3 (en) 2012-08-08
NZ574046A (en) 2012-09-28
US20150050646A1 (en) 2015-02-19
WO2008008986A3 (en) 2008-10-23
CA2659392A1 (en) 2008-01-17
WO2008008986A2 (en) 2008-01-17
EP2447275A1 (en) 2012-05-02
US20120040884A1 (en) 2012-02-16
SG173371A1 (en) 2011-08-29
AU2007272335B2 (en) 2014-03-27
HK1168360A1 (en) 2012-12-28
US20180371547A1 (en) 2018-12-27
US20080152659A1 (en) 2008-06-26
EP2447275B1 (en) 2015-04-01
US7867727B2 (en) 2011-01-11
AU2007272335A1 (en) 2008-01-17
EP2046807A4 (en) 2009-10-28
HK1126223A1 (en) 2009-08-28
EP2046807B1 (en) 2012-03-28
JP2009544280A (ja) 2009-12-17
ATE551350T1 (de) 2012-04-15
EP2479284A2 (en) 2012-07-25
EP2046807A2 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
JP5431151B2 (ja) 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬
JP5100901B2 (ja) 加齢性黄斑変性を処置および診断するための方法および試薬
EP2851432B1 (en) RCA locus analysis to assess susceptibility to AMD
US20100167285A1 (en) Methods and agents for evaluating inflammatory bowel disease, and targets for treatment
CN101160412A (zh) 治疗和诊断年龄相关性黄斑变性的方法和试剂
AU2016204271B2 (en) Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration
HK1172070A (en) Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
AU2013202401A1 (en) Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration
HK1168360B (en) Methods and reagents for treatment of age-related macular degeneration
HK1126223B (en) Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121029

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131009

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131101

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131204

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5431151

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250